id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10171 R37143 |
Blotière (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
4.32 [0.21;90.51] C excluded (control group) |
0/139 2/2,997 | 2 | 139 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10039 R36251 |
Blotière (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 | Cleft lip with or without cleft palate | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 4.13 [0.26;66.42] C | 0/139 1,637/1,875,733 | 1,637 | 139 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9065 R30948 |
Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 | Cleft lip | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 34.33 [0.49;2389.88] C | 0/2 0/52 | 0 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9057 R30916 |
Artama (Oxcarbazepine), 2005 | Cleft lip/ cleft palate | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 1.90 [0.09;39.89] C | 0/99 2/939 | 2 | 99 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 4.64 [0.73;29.40] | 1,639 | 240 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oxcarbazepine) (Controls unexposed NOS) (Mixed indications; 2: Oxcarbazepine) (Controls unexposed, sick) ; 3: Oxcarbazepine;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 10171